(Q68060385)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1537998%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

title

Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1537998%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

1 reference

1 reference

9

E J Topol

1 reference

21 September 2019

4

S G Ellis

1 reference

21 September 2019

6

D J Kereiakes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1537998%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

3

B S George

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1537998%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

2

R M Califf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1537998%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

author name string

T. C. Wall

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1537998

6 October 2022

R. M. Califf

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1537998

6 October 2022

J. K. Samaha

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1537998

6 October 2022

S. J. Worley

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1537998

6 October 2022

K. Sigmon

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1537998

6 October 2022

E. J. Topol

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1537998

6 October 2022

language of work or name

English

0 references

publication date

1 March 1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1537998%20AND%20SRC:MED&resulttype=core&format=json

Journal of the American College of Cardiology

21 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1537998%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1537998%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1537998%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

page(s)

482-489

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1537998%20AND%20SRC:MED&resulttype=core&format=json

A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction

21 September 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Optimal dosage regimens of tissue-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Enhancing thrombolytic efficacy by means of "front-loaded" administration of tissue plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

The use of single plane angiocardiograms for the calculation of left ventricular volume in man

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Advantages and applications of the centerline method for characterizing regional ventricular function

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Thrombolysis with recombinant tissue plasminogen activator in atherosclerotic thrombotic occlusion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Results of high dose intravenous urokinase for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Factors determining improvement in left ventricular function after reperfusion therapy for acute myocardial infarction: primacy of baseline ejection fraction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980259-1

1 reference

7 January 2021

10.1016/S0735-1097(10)80259-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1537998%20AND%20SRC:MED&resulttype=core&format=json

21 September 2019

1 reference